BDNF and central nervous system cancer: Using TCGA analysis, we demonstrated that BDNF-AS is downregulated in GBM and in glioma subtypes that are associated with aggressive phenotypes and poor prognosis, whereas high levels of BDNF-AS are associated with better patient prognosis.